TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04332094
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
Study: NCT00371410
Drug: intravitreal triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01465412
Drug: Preladenant
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
Study: NCT02817763
Drug: sodium dipyrone
Normalized name: dipyrone
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium dipyrone was recommended for all participants after the surgical procedures.
Study: NCT02748213
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral Xeloda, 950 mg/m\^2 twice a day on Days 1 to 14 of each 21-day cycle.
Study: NCT02748213
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
Study: NCT02748213
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
Study: NCT04200651
Drug: Dexamethasone Ophthalmic Insert
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
Study: NCT02389829
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02389829
Drug: Prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02389829
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01170429
Drug: Procaterol hydrochloride
Normalized name: procaterol hydrochloride
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25µg BID for 8 weeks
Study: NCT04069273
Drug: Pembrolizumab Monotherapy
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV
Study: NCT04069273
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 10 mg/kg IV
Study: NCT04069273
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m2 IV
Study: NCT01950468
Drug: DaTscan
Normalized name: DaTscan
DrugBank: Ioflupane I-123 (DB08824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single intravenous dose of 3 to 5 mCi
Study: NCT03441412
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated.
Study: NCT03441412
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated.
Study: NCT02563054
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
Study: NCT02563054
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
Study: NCT00369954
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00369954
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04014205
Drug: Orelabrutinib (ICP-022)
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-022 The drug product is a white, round, uncoated tablet
Study: NCT00151931
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070031
Drug: edotecarin
Normalized name: Edotecarin
DrugBank: Edotecarin (DB04882)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02513160
Drug: Beclomethasone Dipropionate 640
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate 640 mcg BAI
Study: NCT02513160
Drug: Beclomethasone dipropionate via 320 mcg BAI
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
Study: NCT02513160
Drug: albuterol/salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
Study: NCT02513160
Drug: Beclomethasone dipropionate via 320 mcg MDI
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
Study: NCT04574713
Drug: Candesartan Oral Tablet 8 mg
Normalized name: candesartan Oral Tablet
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).
Study: NCT04574713
Drug: Candesartan Oral Tablet 16 mg
Normalized name: candesartan Oral Tablet
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).
Study: NCT01168232
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00780377
Drug: Bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
Study: NCT02797587
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week starter kit followed by 1mg twice daily for 12 weeks.
Study: NCT02797587
Drug: Cytisine
Normalized name: Cytisine
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-daily dosing, range 3-9 mg daily for 25 days.
Study: NCT02797587
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.
Study: NCT02729025
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously once a month using an autoinjector/pen.
Study: NCT01415518
Drug: Drug: ipratropium (AtroventTM)
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
Study: NCT00931528
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
Study: NCT00194402
Drug: Slo-Niacin, atorvastatin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
Study: NCT02416063
Drug: Caudal Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia
Study: NCT02416063
Drug: Intravenous dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia
Study: NCT00118157
Drug: Lapatinib Ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02797587
Drug: Varenicline Placebo
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week starter kit followed by 1 pill twice daily for 12 weeks.
Study: NCT02797587
Drug: Cytisine Placebo
Normalized name: cytisine
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-daily dosing for 25 days.
Study: NCT00118157
Drug: Tamoxifen Citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00782626
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00663936
Drug: T-817MA
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 224 mg T-817 MA once daily
Study: NCT04111289
Drug: -Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~* Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~* Randomization will be performed by Microsoft Excel where random order will be generated for the study population
Study: NCT03182933
Drug: Peripheral Nerve Blockade
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
Study: NCT04169269
Drug: Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulant, subcutaneous injection
Study: NCT04169269
Drug: Rivaroxaban 10 milligram Oral Tablet
Normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anticoagulant, oral
Study: NCT01667718
Drug: Bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth 220mg b.i.d for 2 weeks
Study: NCT01667718
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d.for 2 weeks
Study: NCT01667718
Drug: Levoﬂoxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levoﬂoxacin 0.5 q.d. for 2 weeks
Study: NCT01667718
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d. for 2 weeks
Study: NCT02453932
Drug: Tianzhi granule and placebo identified to donepezil
Normalized name: donepezil and memantine
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
Study: NCT02453932
Drug: Donepezil and placebo identified to Tianzhi granule
Normalized name: donepezil and memantine
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
Study: NCT03764449
Drug: Oral Balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14.
Study: NCT03764449
Drug: IV Balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan.
Study: NCT04372628
Drug: Lopinavir/Ritonavir 400 mg/100 mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/Ritonavir tablets
Study: NCT01037842
Drug: Mitiglinide
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks
Study: NCT01660633
Drug: High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
Normalized name: Propylene Glycol
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
Study: NCT01353599
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 220mcg once daily, for eight weeks
Study: NCT03535792
Drug: Fentanyl/Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.
Study: NCT03535792
Drug: Nalbuphine/Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
Study: NCT01697072
Drug: Rilotumumab
Normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
Study: NCT01697072
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin is an anthracycline cytotoxic agent.
Study: NCT01697072
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Study: NCT02797587
Drug: Nicotine Replacement Therapy Placebo
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth spray dosing based on standard recommendations tapered over 8 weeks.
Study: NCT00513695
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00513695
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03861390
Drug: 60 mg Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
Study: NCT03485417
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: for oral or depot preparation
Study: NCT03485417
Drug: Paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: for oral or depot
Study: NCT04320225
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HD-DXM (orally at 40 mg daily for 4d )
Study: NCT02569125
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4.5 mg/m² daily
Study: NCT01590225
Drug: Boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
Study: NCT01590225
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 24 weeks.
Study: NCT01590225
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 24 weeks.
Study: NCT01590225
Drug: Boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
Study: NCT01590225
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 48 weeks.
Study: NCT01590225
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 48 weeks.
Study: NCT01576679
Drug: Cathflo (Alteplase)
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01576679
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01417156
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg bid
Study: NCT01417156
Drug: Pirfenidoneone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Existing treatment
Study: NCT03411031
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab according to dosing schedule outlined in treatment arms.
Study: NCT03411031
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide according to dosing schedule outlined in treatment arms.
Study: NCT03411031
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert.
Study: NCT01198223
Drug: garlic , nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mouthwash
Study: NCT00933023
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 0.1% topical once daily for 8weeks
Study: NCT00038181
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05063513
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.